Kristina Schwamborn
Overview
Explore the profile of Kristina Schwamborn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iwuajoku V, Ekici K, Haas A, Khan M, Kazemi A, Kasajima A, et al.
Virchows Arch
. 2025 Feb;
PMID: 39964525
Digital pathology is revolutionizing clinical diagnostics by offering enhanced efficiency, accuracy, and accessibility of pathological examinations. This study explores the implementation and validation of digital pathology in a large tertiary...
2.
Lammert J, Dreyer T, Mathes S, Kuligin L, Borm K, Schatz U, et al.
JCO Precis Oncol
. 2024 Oct;
8:e2400478.
PMID: 39475661
Purpose: Rapidly expanding medical literature challenges oncologists seeking targeted cancer therapies. General-purpose large language models (LLMs) lack domain-specific knowledge, limiting their clinical utility. This study introduces the LLM system Medical...
3.
Slotta-Huspenina J, Schwamborn K, Steiger K, Simon R, Kirchhoff F, Buchler J, et al.
Bladder Cancer
. 2024 Jul;
8(3):269-276.
PMID: 38993685
Background: Loss of MHC I expression is a tumoral escape mechanism, part of the process of immunoediting. MHC expression patterns and their prognostic and predictive value have not been studied...
4.
Wang H, Remke M, Horn T, Schwamborn K, Chen Y, Steiger K, et al.
EJNMMI Res
. 2023 Nov;
13(1):99.
PMID: 37971546
Background: Targeting prostate-specific membrane antigen (PSMA) has been highly successful for imaging and treatment of prostate cancer. However, heterogeneity in immunohistochemistry indicates limitations in the effect of imaging and radionuclide...
5.
Kasajima A, Pfarr N, von Werder A, Schwamborn K, Gschwend J, Ud Din N, et al.
Virchows Arch
. 2023 Jul;
483(4):465-476.
PMID: 37405461
Renal neuroendocrine tumors (RenNETs) are rare malignancies with largely unknown biology, hormone expression, and genetic abnormalities. This study aims to improve our understanding of the RenNETs with emphasis of functional,...
6.
Cox A, Klumper N, Stein J, Sikic D, Breyer J, Bolenz C, et al.
Eur Urol
. 2023 Apr;
85(4):328-332.
PMID: 37031005
Urothelial cancer (UC) care is moving toward precision oncology. For tumor biology-driven treatment of metastatic UC (mUC), molecular subtypes play a crucial role. However, it is not known whether subtypes...
7.
Goncalves J, Bollwein C, Noske A, Jacob A, Jank P, Loibl S, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36769215
Immunohistochemical evaluation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 status stratify the different subtypes of breast cancer and define the treatment course. Triple-negative breast cancer (TNBC),...
8.
Klumper N, Ralser D, Ellinger J, Roghmann F, Albrecht J, Below E, et al.
Clin Cancer Res
. 2022 Dec;
29(8):1496-1505.
PMID: 36534531
Purpose: The antibody-drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients with metastatic urothelial...
9.
Konrad S, Schwamborn K, Kruger A, Honert K, Schmitt M, Hellmann D, et al.
Biomark Med
. 2022 Nov;
16(14):1029-1041.
PMID: 36444691
Since reliable response predictors to platinum-based chemotherapy in ovarian cancer (OC) are scarce, we characterize NCALD as a predictive biomarker. NCALD mRNA (n = 100) and protein (n = 102)...
10.
Erlmeier F, Klumper N, Landgraf L, Strissel P, Strick R, Sikic D, et al.
Eur Urol
. 2022 Nov;
83(2):133-142.
PMID: 36372626
Background: The value of programmed cell death ligand-1 (PD-L1) to predict durable responses to immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC) is inconsistent. We hypothesize that the use...